|
|
Use PE-labeled CD19 and FITC-labeled CD22 together to detect the bispecific CD19/CD22 CAR-T expression with high specificity
|
Despite unprecedented successes of anti-CD19 CAR T cells for the treatment of B-ALL, relapses with CD19 loss occur in a large fraction of patients. Some studies have indicated that bispecific CAR-modified T cells targeting both CD19 and CD22 may overcome the limitation of CD19-negative relapse. However, there are some challenges such as high non-specific background, and the difficult to distinguish two CARs during the detection of bispecific CAR expression in clinical trials.
ACROBiosystems has developed the high affinity PE-labeled CD19 (Cat. No. CD9-HP2H3) and FITC-labeled CD22 (Cat. No. SI2-HF2H6), which can specific detect the CD19 and CD22 CARs expression by one step staining. In addition, fluorescent-labeled CD19/CD22 combining with biotinylated CD22/CD19 also ideal for the detection of two CARs expression simultaneously.
Product Features
>>> High specificity verified by FACS
>>> PE/FITC/Biotin-labeled proteins are available
Validation Data by FACS
Cat. No：SI2-HF2H6
Product：FITC-Labeled Human Siglec-2 / CD22 Protein, His Tag
293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were stained with FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6, 10 µg/mL) and FITC-labeled Protein Control. Non-transfected 293 cells and FITC-labeled Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human Siglec-2, His Tag (Cat. No. SI2-HF2H6) (QC tested).
Cat. No：SI2-H82F8
Product：Biotinylated Human Siglec-2 / CD22 Protein, Fc,Avitag™
293 cells were transfected with anti-CD22-scFv and RFP tag. 2e5 of the cells were first stained with Biotinylated Human Siglec-2, Fc,Avitag (Cat. No. SI2-H82F8, 10 μg/mL) and Biotinylated Protein Control, followed by FITC Streptavidin. Non-transfected 293 cells and Biotinylated Protein Control were used as negative control. RFP was used to evaluate CAR (anti-CD22-scFv) expression and FITC was used to evaluate the binding activity of Biotinylated Human Siglec-2, Fc,Avitag (Cat. No. SI2-H82F8).
Cat. No：CD9-HP2H3
Product：PE-Labeled Human CD19 (20-291) Protein, His Tag
|
|
1e6 of the anti-CD19 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HP2H3). PE Streptavidin was used as negative control (QC tested)
|
Cat. No：CD9-HF2H2
Product：FITC-Labeled Human CD19 (20-291) Protein, His Tag
293 cells were transfected with anti-CD19-scFv and RFP tag. 2e5 of the cells were stained with FITC-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HF2H2, 10 µg/ml) and FITC-labeled protein control. Non-transfected 293 cells and FITC-labeled protein control were used as negative control. RFP was used to evaluate CAR (anti-CD19-scFv) expression and FITC was used to evaluate the binding activity of FITC-Labeled Human CD19 (20-291), His Tag (Cat. No. CD9-HF2H2) (QC tested).
Cat. No：CD9-H82E9
Product：Biotinylated Human CD19 (20-291) Protein, His,Avitag™ (SPR verified)
| 